🚀 Enjoy a 7-Day Free Trial Thru May 05, 2024! ✨

Lixte Biotechnology Holdings Inc

FRA:8640 (USA)

€ 6.10 (0%) Feb 14

At Loss

14.82

€ 5.61M ($ 6.00M)

€ 4.11M ($ 6.54M)

Volume:

-

Avg Vol (2M):

-

Warning! GuruFocus detected 1 Severe warning sign with 8640. Try a 7-Day Free Trial to check it out.

Also Trade In:

Volume:

-

Market Cap €:

5.61M

6.00M

At Loss

Avg Vol (2M):

-

Enterprise Value €:

4.11M

Enterprise Value $:

6.54M

14.82

Lixte Biotechnology Holdings Inc (FRA:8640) Stock News, Headlines & Updates

Lixte Biotechnology Holdings Inc Stock News from GuruFocus

Total 43

Feb 07, 2024

Lixte Biotechnology Holdings Inc at Issuer Direct Planet MicroCap Showcase (Virtual) Transcript

GuruFocus Research • 3:25pm

Lixte Biotechnology Holdings Inc at Benzinga Global Small Cap Conference (Virtual) Transcript

GuruFocus Research • 3:25pm

Oct 16, 2023

LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

Marketwired • 8:00am

Oct 09, 2023

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

Marketwired • 8:00am

Sep 26, 2023

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Marketwired • 8:00am

Sep 20, 2023

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

Marketwired • 8:00am

Jul 20, 2023

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

Marketwired • 4:00pm

Jul 18, 2023

LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

Marketwired • 7:00am

Jul 17, 2023

Preclinical Results of LIXTE Biotechnology's Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE's Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy

Marketwired • 8:00am

Jun 23, 2023

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Marketwired • 8:00am

Feb 14, 2023

LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH

sperokesalga • 1:00pm

Feb 07, 2023

LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

Stock market mentor • 12:00pm

Apr 14, 2022

LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

GuruFocusNews • 6:00pm

Apr 12, 2022

LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market

GuruFocusNews • 1:00pm

LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations

GuruFocusNews • 8:00am

Mar 16, 2022

LIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor Conference

GuruFocusNews • 8:00am

Jan 12, 2022

Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100

GuruFocusNews • 8:00am

Nov 22, 2021

LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE'S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS

GuruFocusNews • 9:00am

Jul 13, 2021

Lixte Biotechnology Comments on Outside Research Citing LB-100's PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer

Marketwired • 9:00am

Jun 02, 2021

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

Marketwired • 9:01am

May 12, 2021

LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS

Marketwired • 9:00am

Mar 03, 2021

Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference

Marketwired • 11:02am

WestPark Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)

Business Wire • 7:00pm

Mar 02, 2021

WallachBeth Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc.

PRNewswire • 3:00pm

Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering

Marketwired • 11:00am

Mar 01, 2021

Lixte Biotechnology Announces $4.19 Million Registered Direct Offering

Marketwired • 11:03am

Feb 24, 2021

Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference

Marketwired • 11:00am

Jan 19, 2021

Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte's Lead Compound LB-100 to Treat Small Cell Lung Cancer

Marketwired • 11:00am

Dec 03, 2020

Lixte Biotech Holdings Inc (LIXT) President and CEO John S Kovach Bought $100,225 of Shares

GuruFocus Research • 8:15pm

Dec 01, 2020

WallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten Public Offering for Lixte Biotechnology Holdings, Inc.

PRNewswire • 3:00pm

Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq

Marketwired • 3:00pm

Nov 30, 2020

WestPark Capital Announces Closing of $5,700,000 Follow-On Offering and NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT, LIXTW)

Business Wire • 3:00pm

Jul 21, 2020

Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer

Marketwired • 11:01am

Apr 30, 2020

Lixte Biotechnology's PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors

Marketwired • 11:00am

Dec 04, 2019

First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology's LB-100 to Enter Recurrent Malignant Brain Tumors

Marketwired • 11:00am

Aug 06, 2019

The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings' LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas

Marketwired • 11:03am

Jul 18, 2019

First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology's LB-100 in Low or Intermediate-1 Risk Myelodysplastic Syndrome

Marketwired • 11:05am

Jun 25, 2019

Lixte Biotechnology's PP2A Inhibitor, LB-100, Improves Brain Function and Motor Impairment in a Mouse Model of Angelman Syndrome, a Rare Human Neurodevelopmental Disorder

Marketwired • 11:01am

May 15, 2019

Lixte Biotechnology's LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100's Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors

Marketwired • 11:02am

Nov 05, 2018

FDA Approves Lixte Biotechnology's IND to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center

Marketwired • 3:02pm

Total 43

Show

Entries

Headlines

Total 0

No recent news

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Follow Us

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.